At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 18 enrolled
Drug / intervention
Sunitinib +2 moredrug
Likely dose
Sunitinib 25mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of Gemcitabine, Cisplatin, and Sunitinib (GC-S) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer
In Brief
A Phase 2 clinical trial evaluating Sunitinib, Gemcitabine, and 1 other intervention for Bladder Cancer and Urinary Bladder. Completed, enrolled 18 participants across 5 sites.
Detailed Summary
The purpose of this study is to find out if using the combination of standard chemotherapy (gemcitabine and cisplatin) plus this new targeted pill (sunitinib) can help shrink your tumor before you undergo surgery for your bladder cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBladder Cancer, Urinary Bladder
CountriesUnited States
CollaboratorsPfizer
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2009
First PostedFeb 2009
Primary CompletionNov 2012
TodayJul 2026
First PostedFeb 19, 2009
Enrollment StartFeb 1, 2009
Primary CompletionNov 1, 2012
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 17.4 years ago
Interventions
Sunitinibdrug
Sunitinib will be administered at a dose of 25mg orally once daily for 2 consecutive weeks followed by a 1 week rest period.
Gemcitabinedrug
Gemcitabine 1,000 mg/m\^2
cisplatindrug
cisplatin 35 mg/m\^2 will be administered intravenously on days 1 and 8.